glp-1 for alzheimer's Frontiers GLP-1 Drugs and Brain Health:

Are there specific clinical criteria required for approval (e.g., BMI thresholds, sustained weight requirements, step therapy such as participation in a weight management program)

J Phys Soc Japan 74:28532859

The same features of those previously described in non-genital pigmented Bowens disease confirmed the value of RCM in addressing the correct diagnosis by narrow down the differential diagnosis with clinically similar benign and malignant pigmented lesions, including melanoma.2 In conclusion, early diagnosis and treatment of penile Bowens disease are important to prevent progression to invasive squamous cell carcinoma, which may occur in up to 30% of cases, and the need for extensive mutilating surgery.5 However, Bowens disease diagnosis can be challenging because it may be difficult to distinguish from melanoma, even using dermoscopy

People with neuromuscular diseases (like Lou Gehrigs disease, myasthenia gravis, or Lambert-Eaton syndrome) are at a higher risk of serious side effects

Another crucial target involved in metabolic diseases and cognitive impairment is the mammalian target of rapamycin (mTOR)

Biochem Biophys Res Commun , 1973, 54(2): 562-566